Upcoming Cancer Clinical Trials To Begin INV043

Some good news regarding Clinical Trials

R&D activities during the quarter June 2023

Invion is developing the Photosoft™ technology for the treatment of cancers and infectious
diseases and atherosclerosis (AID).

The Company’s priority during the quarter is to work with its partners, including the Peter
MacCallum Cancer Centre and Hudson Institute of Medical Research, to complete the
preparatory groundwork for the upcoming clinical trials. The drug discovery work on both
topical and intravenous (IV) formulations of INV043, the lead drug candidate, have been
completed.

Meanwhile, Invion and its partners have made significant progress on the pre-clinical studies
required for the Phase 1trials, including having largely completed this work for the topical drug
product, which will be used in the skin cancer and anogenital cancer trials.

The Company is progressing on the pre-clinical studies for the IV drug product that will be used
in future solid tumour clinical trials.

Further, Invion is working with IDT Australia Limited (ASX: IDT) on manufacturing the Active
Pharmaceutical Ingredient (API) drug substance, and is also working on manufacturing drug
products for both topical and IV administrations.

Additionally, drug discovery studies using Photosoft on infectious diseases and atherosclerosis
are continuing with research partners including the Australian Centre for Antimicrobial
Resistance Ecology (ACARE), which is part of the University of Adelaide. Invion will release
further results from these studies as they become available.